Bednasz Cindy J, Sawyer Joshua R, Martinez Anthony, Rose Patrick G, Sithole Samantha S, Hamilton Holly R, Kaufman Farzia S, Venuto Charles S, Ma Qing, Talal Andrew, Morse Gene D
School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA.
School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA.
Future Virol. 2015;10(8):981-997. doi: 10.2217/fvl.15.64.
Chronic hepatitis C virus (HCV) is a global epidemic, affecting approximately 150 million individuals throughout the world. The implications of HCV infection have been magnified in those who are infected with both HCV and the HIV as liver disease progression, liver failure and liver-related death are increased, particularly in those without well-controlled HIV disease. The development of direct-acting antiviral agents for HCV that allow shorter treatment periods with increased efficacy and decreased adverse events have greatly changed the outlook for HCV-infected individuals. With these advancements, growing treatment options for the coinfected population have also come. This review will address pharmacotherapy issues in the HIV/HCV coinfected population.
慢性丙型肝炎病毒（HCV）是一种全球性流行病，影响着全球约1.5亿人。丙型肝炎病毒和人类免疫缺陷病毒（HIV）双重感染者中，HCV感染的影响因肝病进展、肝衰竭及肝相关死亡增加而被放大，尤其是在HIV病情控制不佳者中。用于HCV的直接作用抗病毒药物的出现，使得治疗周期缩短、疗效提高且不良事件减少，极大地改变了HCV感染者的前景。随着这些进展，针对合并感染人群的治疗选择也越来越多。本综述将探讨HIV/HCV合并感染人群的药物治疗问题。
